Global Henatologic Malignancies Testing Market Size Likely to Grow at a CAGR of 14.4% By 2035

It is projected that the global Henatologic Malignancies Testing market size is USD 3.28 billion in 2025, and it is also projected that the market size would increase to USD 3.72 billion in 2026, and at an approximate of USD 12.47 billion in 2035, at an annual CAGR of 14.4%.

Henatologic Malignancies Testing Market Revenue and Trends

The Henatologic Malignancies Testing Market has been enjoying a high growth rate due to the rising cases of bleeding disorders, including, but not limited to, congenital fibrinogen deficiency, bleeding due to traumas, and bleeding as a complication of surgery. The concentrates are vital in replenishing the fibrinogen levels and proper formation of blood clot, and they are vital in emergency, trauma, and other complicated surgeries. The trend of increased demand of rapid-acting and targeted hemostatic therapies is also driving an accelerated growth in the market that is mainly in the critical care environment. Moreover, the plasma fractionation and purification technologies are improving the product safety, efficacy, and availability, which contribute to the increased clinical usage.

What are the Factors that Significantly Exert an Influence on the development of Henatologic Malignancies Testing Market?

The main factors that control growth of the Henatologic Malignancies Testing market include the rising rate of trauma cases, surgery, and inherited bleeding disorders including afibrinogenemia and hypofibrinogenemia. Medical practitioners are also using fibrinogen concentrates over the conventional such as cryoprecipitate because of their standardized dosages, quick preparation, and fewer risks of infectious agents. This change is already helping to change the outcome of patients, especially in emergency and critical care environments where coagulation management is crucial in emergency situations.

The further development of the plasma fractionation and biotechnology processes that allow to increase the safety, purity, and availability of products is another significant reason that encourages the growth of the market. Better access to advanced hemostatic therapies is being enhanced by greater investments in the healthcare infrastructure particularly in emerging economies. Furthermore, facilitating government programs, increasing consciousness of health care providers, and the increase in the use of patient blood management (PBM) programs are also increasing market growth. All these factors will keep the demand of human fibrinogen concentrates very high in the entire world within the forecast period.

Segment Insight

By Product

Kits occupy an important segment of the Henatologic Malignancies Testing market because they are widely used in routine diagnostics and standardized procedures in laboratories and hospitals. Such kits such as PCR, immunoassay and NGS-based panels allow the correct, reproducible and high-throughput testing that is critical with the growing global rate of blood cancers. They are very scalable to large volumes of samples because of their ease of use, regulatory approvals, and compatibility with automated platforms. Also, adoption is further being driven by the increasing access of companion diagnostic kits in line with targeted therapies. Compared to it, services rely on outsourcing and extended turnaround time, but services are becoming more popular in the case of specialized and complex testing needs.

By Platform

Flow cytometry has captured a significant share of the Hematologic malignancies testing market since it is a vital tool in the diagnosis, classification and monitoring of diseases specifically in leukemia and lymphoma. It provides the possibility to analyse many cellular markers within the shortest possible time and be able to immunophenotype cancer cells. It is a commonly utilized technology because it is a first-line diagnostic tool because it is fast, reliable, and cost-effective as opposed to other advanced genomic platforms. Moreover, it is dominant due to its availability in numerous hospitals and diagnostic laboratories. Although new technologies like next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH) facilitate a more detailed study of the disease at a molecular scale, flow cytometry is the basis of hematologic cancer diagnostics.

By End Use

Hematologic Malignancies Diagnostic labs are mainly ruling the hematologic malignancies testing market because they can handle large volumes of testing using the advanced technological infrastructure. Flow cytometry, NGS, and molecular diagnostic systems are advanced platforms that are present in these laboratories and allow conductors to carry out effective and thorough testing of cancer. They are cost-effective, automatable, and have standardized procedures that guarantee the reliability and consistency of the results and are therefore the best option when the high-volume testing is to be done. Also, hospitals often refer to such labs when complex diagnostic tests are needed, to increase the efficiency and decrease the workload. Although reference laboratories are becoming increasingly more significant in specialized and high-end testing, diagnostic laboratories remain the market leaders because they can be scaled and because they have technical expertise.

Outlook

According to recent forecasts, the Henatologic Malignancies Testing market is expected to grow steadily between 2026 and 2035, due to the growing prevalence of bleeding disorders, the rise in cases of trauma, and the rising number of surgical interventions in the world. Fibrinogen concentrates are playing a critical role in the market regarding the management of acute bleeding like trauma, postpartum bleeding and complicated surgical operations. The fibrinogen concentrates provide faster reconstitution, standard dose, and better safety profiles, unlike the previous blood components, e.g. cryoprecipitate, which is mostly advantageous in clinical outcomes.

Regional Insights

Henatologic Malignancies Testing market is set to experience most rapid growth in Asia Pacific due to the rising healthcare, more access to more advanced treatment procedures, and the rising cases of trauma and surgeries. Large economies like China, India, and Japan are also on the move to intensify emergency care infrastructure and to enhance the access to life-saving treatments. Moreover, the high number of patients, increase in health care investment and increased ability to detect rare coagulation disorders are also leading to increased product adoption. The government efforts at enhancing the practice of critical care delivery and transfusion are also driving quick growth in the market in the region.

The robust clinical uptake of the use of plasma-derived therapeutic and well-developed health systems are driving the market growth in Europe. The area is advantaged of systematic intervention strategies, a good understanding of the importance of coagulation management, and favorable rebate schemes. The growing popularity of patient blood management tactics, as well as the availability of major companies engaged in plasma fractionation, are also contributing to the consistent demand of the fibrinogen concentrates in surgical and emergency care facilities.

North America remains a highly developed market, which is backed by advanced healthcare infrastructure and large number of complex surgery procedures. It is also evidenced by the high level of adoption of advanced transfusion practices and rapid-response treatment protocols in the field of trauma care. The demand is also supported by the constant technological progress, the growth of attention to the enhancement of clinical outcomes, and the ongoing commitment to research and product development. A combination of these forces is maintaining steady growth in the market of the United States and Canada.

Report Scope

Recent Developments

• In October of 2025, Integrated DNA Technologies, Inc. collaborated with Hamilton on continuously evolving an automated, customizable next-generation sequencing (NGS) workflow to provide comprehensive genomic profiles. Based on the liquid handling platforms of Hamilton, they are platform-agnostic solutions that aim to improve the efficiency and scalability of both solid tumor and hematologic cancer research systems.

List of the prominent players in the Henatologic Malignancies Testing Market:

• Abbott Laboratories

• Adaptive Biotechnologies

• ARUP Laboratories

• Bio-Rad Laboratories Inc.

• ICON plc

• Illumina Inc.

• Invivoscribe Inc.

• Laboratory Corporation of America Holdings

• NeoGenomics Laboratories

• OHSU’s Knight Diagnostic Laboratories

• QIAGEN N.V.

• Quest Diagnostics

• Sysmex Corporation

• Tempus Labs Inc.

• Bio-Techne

• DiaSorin S.p.A

• Thermo Fisher Scientific Inc.

• Bruker Corporation

• Vela Diagnostics

• Amoy Diagnostics Co. Ltd.

• Integrated DNA Technologies Inc.

• Others

The Henatologic Malignancies Testing Market is segmented as follows:

By Product

• Kits

• Services

By Platform

• Next-Generation Sequencing

• Fluorescence In-Situ Hybridization

• Immunohistochemistry

• Flow Cytometry

• Other

By End Use

• Specialty Clinics and Hospitals

• Diagnostic Laboratories

• Reference Laboratories

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America